Research

Hormonal

GLP-1 receptor agonists (specifically Liraglutide 3.0 mg/day) induce significant weight loss (median 63% achieving ≥5% loss) and reduce hepatic steatosis, potentially through mechanisms independent of weight loss.

If lifestyle changes are insufficient, GLP-1 receptor agonists like Liraglutide (3.0 mg/day) are highly effective. They help patients lose significant weight (average 8%) and directly reduce liver fat and inflammation. This is particularly relevant for patients with Type 2 Diabetes.

GoodSupportsHIGH confidence
Liraglutide 3.0 mg/day has proven to induce 8.0 ± 6.7% of weight loss [105] and 63% median rate of achieving at least 5% weight loss [106]. ... some of the beneficial effects of liraglutide on NAFLD could be independent of weight loss. In rodents, liraglutide prevented the development of NAFLD and attenuated the expression of pro-inflammatory cytokines [107–110].
Amélio F. Godoy‐Matos et al. · Diabetology & Metabolic Syndrome · 2020

Why this rating

Cites RCTs and meta-analyses (refs 105-110), though many are in T2D patients.

Source

NAFLD as a continuum: from obesity to metabolic syndrome and diabetes

Amélio F. Godoy‐Matos et al. · Diabetology & Metabolic Syndrome · 2020

DOI 10.1186/s13098-020-00570-y

narrative_reviewCited 638×
Read the paper
DOI resolved against Crossref · corpus check 2026-06-10

This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →